Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

Overview

Dual-energy CT (DECT) provides information on the blood volume in tumors and lymph nodes. As tumors respond to treatment, preliminary data suggests that the blood volumes changes as well. Investigators are therefore using DECT to test whether it can be used on radiation treatment to rapidly assess response to treatment.

Full Title of Study: “Pilot Study of Dual-Energy Computed Tomography in Stage III Non-Small Cell Lung Cancer”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 2019

Clinical Trial Outcome Measures

Primary Measures

  • Change in the tumor’s maximum iodine related attenuation (IRA) from baseline to on-treatment DECT.
    • Time Frame: 0, 1, 3, 5
    • This change in the maximum IRA will be compared with the change in the maximum standardized uptake value (SUV max) between baseline PET-CT and follow-up PET-CT at 3 months after treatment. For patients undergoing surgery, this change in the maximum IRA will be compared between patients who have a complete pathologic response, and those patients who do not.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients aged greater than 18 years with a diagnosis of stage III non-small cell lung cancer. – Planned treatment with either definitive chemoradiotherapy or preoperative chemoradiotherapy followed by surgical resection. – PET-CT study within 4 weeks of next available DECT study. – Patients must have measurable primary and nodal disease, defined by at least one lesion (primary and lymph node) greater than 1 cm. – Kidney function sufficient to tolerate iodine-based CT contrast. – No allergy to iodine-based contrast. – Ability to understand and the willingness to sign informed consent. Exclusion Criteria:

  • Participants with a prior history of thoracic radiotherapy. – Participants may not be receiving any other study agents. – Inability to tolerate CT contrast – Pregnant women are excluded from this study because radiotherapy has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with radiotherapy, breastfeeding should be discontinued if the mother is treated with radiotherapy. These potential risks may also apply to other agents used in this study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rush University Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.